ERAS
Erasca Inc
NASDAQ · Biotechnology
$12.29
+0.41 (+3.45%)
Performance
1D
—
1W
+15.83%
1M
+97.27%
3M
+420.76%
6M
+658.64%
1Y
+649.39%
YTD
+242.34%
Open$11.94
Previous Close$11.88
Day High$12.47
Day Low$11.90
52W High$12.47
52W Low$1.01
Volume4.30M
Avg Volume5.48M
Market Cap3.80B
P/E Ratio—
EPS$-0.45
SectorBiotechnology
Volume Analysis
0.78x average volume
Technical Indicators
SMA 50
$6.03
Above
SMA 200
$2.82
Above
RSI (14)
77.7
Overbought
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
15 analysts
Price Target
+100.6% upside
Current
$12.29
$12.29
Target
$24.65
$24.65
$19.75
$24.65 avg
$31.92
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 897.62M | 918.48M | 827.43M |
| Net Income | -100,463,137 | -95,918,574 | -115,001,691 |
| Profit Margin | -11.2% | -10.4% | -13.9% |
| EBITDA | -104,291,949 | -115,509,109 | -110,721,792 |
| Free Cash Flow | -130,963,293 | -137,514,931 | -125,568,165 |
| Rev Growth | +16.3% | +1.8% | +8.3% |
| Debt/Equity | 0.25 | 0.25 | 0.19 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |